The global depyrogenated sterile empty vials market share is projected to accumulate substantial returns by 2026. Depyrogenation refers to the process of removing a pyrogen from a substance, instrument or container or a pharmaceutical container.

Depyrogenated sterile empty vials market, with respect to the product landscape, is segmented into 2ml, 5ml, 10ml, 20ml and more than 20ml. Among these, 5ml segment held a 30% market share in 2019. This growth can be credited to the consistent usage of 5ml vials for cryogenic storage for cells and fluids, thereby ensuring protection to the sample.

The market demand for 10ml vials, pre-assembled with stopper and aluminum crimp steal is rising. The 10ml depyrogenated sterile empty vials market is likely to record a CAGR of 8.5% through 2026, since maximum number of treatments involve usage of 10ml vials.

Furthermore, these sterile vials are used for mixing various medications and drugs for injection. The sealed top gives easy insertion of needle, thereby keeping the injected liquids safely contained for mixing.

The vials are mostly used in the medical field, especially for storing specimen collections and diagnostics. One of the main uses for vials in the medical field is for placement of fluid specimens. These vials are very important, and the medical field cannot do without them.

Rising adoption of more than 20 ml vials in clinical and research laboratories will foster the segmental growth. Vials with more than 20 ml size are capable of storing more amount of medicines in the form of liquid and can also store powders or tablets.

Plastic vials segment is projected to record a CAGR of more than 8% in the depyrogenated sterile empty vials market. Plastic vials are less prone to delamination and breakage as compared to the glass-based vials. Vials made from plastic are also a light material choice.

These vials also give better thermal insulation, thereby allowing them to keep their contents at the right temperature at all times.

With respect to end-user spectrum, the clinical labs segment is projected to record a CAGR of more than 7% owing to growing demand of depyrogenated sterile empty vials for sample collection and storage.

Contract manufacturing organization (CMOs) are expected to emerge as prominent growth avenues. CMOs provide drug development and drug manufacturing services to the pharmaceutical industry. These organizations enable pharmaceutical companies to outsource some aspects of their business and free up their valuable time to help them focus on their drug marketing and drug discovery efforts.

The CMOs segment recorded a market valuation of more than $160 million in 2019 owing to the significant time and cost saving that is associated with the usage of ready-to-use empty sterile vials.

From a regional frame of reference, the Europe depyrogenated sterile empty vials sector accounted for a market share of more than 40% in 2019 due to growing number of labs, research institutes, and biopharmaceutical firms in the region.

The Europe biotech market is considerably attractive to investors due to several reasons ?“ it is a robust hot spot throughout geographies, therapeutic areas, modalities, and industry expertise and powerhouse research to support innovation and basic science, and houses an abundant pool of high-caliber talent.

The Latin America depyrogenated sterile empty market is also estimated to show considerable growth, with an anticipated CAGR of approximately 8.2% owing to the presence of high quality manufacturing units in the region. This rising number of manufacturing units is primarily expected to drive the regional market growth.

The global pharmaceutical market obtained a market valuation of approximately $934.8 billion in 2017 and is anticipated to reach over $1,170 billion by 2021, growing at a rate of 5.8%. The of Middle East and North Africa has been marked for quick expansion when it comes to its pharmaceutical sector.

The Middle East & Africa depyrogenated sterile empty vials market is likely to record a CAGR of more than 7% due to increasing government assistance for the manufacturing of innovative packaging solutions for pharmaceutical products.

The governments across the region are focusing on the well-being of MEA’s growing population and improving healthcare services. They are also concentrating on providing safe and timely delivery of supplies and pharmaceuticals products, thereby leading to a promising future for pharmaceutical industry in the region.